Dbv technologies announces plan to implement ads ratio change

ChÂtillon, france, november 11, 2024 dbv technologies announces plan to implement ads ratio change dbv technologies (euronext: dbv – isin: fr0010417345 – nasdaq stock market: dbvt—cusip: 23306j200), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced plans to change the ratio of its american depositary shares (“adss”) to its ordinary shares (the “ads ratio”), nominal value €0.10 (ten cents) per share, from the current ads ratio of one (1) ads to one (1) ordinary share to a new ads ratio of one (1) ads to five (5) ordinary shares (the “ads ratio change”). the company anticipates that the ads ratio change will be effective on or about november 29, 2024 (the “effective date”).
DBVT Ratings Summary
DBVT Quant Ranking